Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 4343-4351, December 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Groopman, J. D.
Right arrow Articles by Wogan, G. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Groopman, J. D.
Right arrow Articles by Wogan, G. N.

Nuclear Distribution of Aflatoxin B1 and Its Interaction with Histones in Rat Liver in Vivo1

John D. Groopman2, William F. Busby, Jr. and Gerald N. Wogan

Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

The distribution and retention of [3H]aflatoxin B1 (AFB1) residues in rat liver nuclear fractions were determined at 0.5, 2, 12, and 36 hr following administration of a single i.p. dose of [3H]AFB1 (1 mg/kg body weight). Approximately 85 to 90% of the nuclear-bound AFB1 was associated with chromatin 2 hr after aflatoxin treatment, with the remainder present in the nucleoplasmic fraction. Further fractionation of the chromatin showed that approximately 80% of the aflatoxin residues was bound to the DNA, 10% was removed by dialysis, and the remaining 10% was recoverable in the dialyzed chromatin protein fraction. The apparent rate of removal of aflatoxin residues from DNA was twice as fast (t1/2 = 12 hr) as that from the chromatin proteins (1/2 = 24 hr).

Liver nucleoplasmic and chromatin proteins were separated by sodium dodecyl sulfate:polyacrylamide gel electrophoresis. No major differences were observed in the Coomassie Blue dye-binding patterns of control and AFB1-treated animals for at least 36 hr postdosing. Although no significant radiolabeled protein peaks were detected in the nucleoplasmic fraction, two major peaks, accounting for 50 to 60% of the total activity applied to the gel, were observed at each time point in the chromatin protein fraction, with apparent molecular weights of 15,000 and 30,000. Approximately 5 to 10% of the total nuclear-bound aflatoxin residues were associated with these proteins, which were identified as histones by their extraction in 0.25 N HCI and their fractionation patterns on polyacrylamide gel filtration columns and acid:urea gel electrophoresis.

Specific activity measurements demonstrated that histone H1 was the major protein target for [3H]AFB1 residue binding with an adduction level 3 to 4 times higher than that for any other histone. A linear, dose-dependent relationship for the binding of [3H]AFB1 residues to DNA, histone H1, and the total histone population was noted over a 16-fold dose range (0.125 to 2.0 mg AFB1 per kg).

Turnover rates of rat liver histones as a function of AFB1 exposure were determined by labeling the amino acids of histones by i.p. injection of sodium [14C]bicarbonate 22 hr prior to treatment with the toxin and sacrificing the animals up to 4 days following the dosage protocol. The half-life of histone H1 and the total histone population was identical (approximately 3.5 days) in both control and AFB1-treated rats. However, the rate of removal of [3H]AFB1 residues following either a 0.125-or a 1.0-mg/kg dose was 3 to 4 times faster (t1/2 = approximately 1 day) than was the decrease in specific activity of the 14C-labeled histone backbone.

1 Part of this work was presented at the 1979 Annual Meeting of the American Association for Cancer Research (22). Financial support was provided by Grant 5 P01 ES 00597 from the NIH.

2 Present address: Laboratory of Experimental Pathology, Building 37-3A07, National Cancer Institute, NIH, Bethesda, Md.

Received 2/12/80. Accepted 8/15/80.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.